Once Versus Twice Bisoprolol Dosage Regimen in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft Surgery
NCT ID: NCT05730413
Last Updated: 2023-07-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
122 participants
INTERVENTIONAL
2021-08-25
2023-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery
NCT03800264
Predictors of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: A Prospective Cohort Study
NCT04193813
Effect of Genetic Polymorphism on the Occurrence of Post-Operative Atrial Fibrillation After CABG
NCT03871647
Carvedilol Versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery
NCT00198614
Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events
NCT02706860
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Once Daily Regimen
Patients who take bisoprolol 5 mg per day.
Bisoprolol
Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
Twice Daily Regimen
Patients who take bisoprolol 2.5 mg twice per day.
Bisoprolol
Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bisoprolol
Bisoprolol dose was divided to be taken as 2.5 mg twice per day from hospital admission to discharge.
Bisoprolol
Bisoprolol was taken as 5 mg per day from hospital admission till discharge.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with coronary heart disease or myocardial infarction and scheduled for coronary artery bypass surgery
Exclusion Criteria
* History of Sick sinus syndrome, sinoatrial heart block
* History of valve replacement
* Permanent Pacemaker
* LVEF less than 30%
* Unstable Heart failure
* Cardiogenic shock
* Sustained systolic blood pressure less than 100 mmHg or HR less than 50 bpm at recruitment
* Severe chronic obstructive airway disease
* Severe asthma unless was on previously tolerated bisoprolol dose
* Uncontrolled diabetes mellitus unless was on previously tolerated bisoprolol dose
* Pregnant/Lactation
* Previous recent stroke
* Creatinine clearance less than 30 ml/min
* End stage liver disease (liver cirrhosis)
* Drug dependance history
* Untreated phaeochromocytoma
* Vasospastic angina
* Thyrotoxicosis
* History of advanced staged of peripheral vascular disease
* Hypersensitivity
* Patients on any other beta-blocker other than bisoprolol
* Patients on bisoprolol higher than 5 mg/day.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reem Ihab Farouq
Teaching assistant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Reem Ihab, Bsc
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
El-Demerdash Cardiac Academy Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Reem Ihab, Bsc
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL(2776)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.